Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY5016 in Heart Failure Patients
2009-009983-29Phase 2Terminated
- Sponsor
- Relypsa, Inc.
- Start
- May 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperkalemia and heart failure (HF) comparing RLY5016 with Placebo (2 arms). Primary endpoint: Change from baseline in serum potassium. Started May 2009; status: terminated.
02
Drugs
patiromer
03
Conditions
hyperkalemiaheart failure (HF)
Beyond the preview
Go deeper on 2009-009983-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009983-29.